PainReform Ltd.
http://www.painreform.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PainReform Ltd.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Deals Shaping the Medical Industry (9/2008)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.
PainReform licenses Encore's post-surgical pain product
The pain management company PainReformhas entered into its first major licence agreement by signing a deal withEncore Therapeutics, which gives the Israeli firm exclusive North American rights to Encore's post-surgical pain product, ETI-211, as well as the option to expand the agreement to other countries including Japan and the EU.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice